StreetAlpha.app
Home › Stocks › NKTX

Nkarta, Inc. (NKTX)

Healthcare
$1.25
▲ +3.31%
LAST CLOSE · NOV 17

Nkarta develops engineered natural killer cell therapies for autoimmune diseases, led by its candidate NKX019. It last closed at $1.25 on Nov 17, up 3.31% on the day.

AI Auto Pilots
Is NKTX in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$0
Net income
−$104.1M
EPS (diluted)
−$1.41
Free cash flow
−$89.9M
Valuation
Market cap
$89.6M
71.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$48.4M
At Sep 30
Shareholder equity
$215.7M
Shares outstanding
71.7M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $0$0FY2025

From NKTX's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 5).

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated NKTX in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 860.0% upside

Based on 1 analyst who set a price target on NKTX in the past 90 days. The average target is $12.00, with a high of $12.00 and a low of $12.00, compared with the last close of $1.25.

Low $12.00Avg $12.00High $12.00
Blue marker: last close $1.25
Highest target$12.00
Average target$12.00
Lowest target$12.00
Latest rating changes
HC Wainwright & Co.Assumed coverage
Nov 2Buy$12
StifelMaintained
Aug 14Buy$10
HC Wainwright & Co.Maintained
Aug 11Buy$14
DateFirmActionRatingPrice target
Nov 2HC Wainwright & Co.Assumed coverageBuy$12
Aug 14StifelMaintainedBuy$10
Aug 11HC Wainwright & Co.MaintainedBuy$14
Loading…

Technical Analysis

NKTX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 25% below its 20 day and 70% below its 50 day average. It is 99% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot at $1.22, and the nearest resistance the Pivot R1 at $1.30.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 14.4%/day
Key levels
$3.7252 week high+197.6%
$2.48200 day average+98.4%
$2.37100 day average+89.6%
$2.1350 day average+70.4%
$1.84Swing high (Nov 6)+47.2%
$1.5620 day average+24.8%
$1.30Pivot R1+4.0%
$1.25Last close
$1.22Pivot−2.4%
$1.18Pivot S1−5.6%
$1.13Swing low (Nov 9)−9.6%
$1.1052 week low−12.0%
Indicators
RSI (14)32.95Weak, oversold below 30Neutral
MACD-0.23Below its signal lineBearish
Stochastic15.2Near the bottom of its rangeOversold
ADX (14)45.3Strong downtrend
Williams %R-80.3Oversold below −80, overbought above −20Oversold
CCI (20)-132.0Oversold below −100, overbought above 100Oversold
Rate of change−18.3%Change over 10 sessionsBearish
ATR (14)$0.18Typical daily range, 14.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NKTX

What happened before

See how NKTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NKTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NKTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NKTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

NKTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●57 buying vs 64 selling
  • ●Held by funds -0.3 pts
  • ▼Funds holding -12
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding124136−8.8%
In funds' top 10110.0%
Held by funds82.5%82.8%−0.3 pts
New / increased7 / 5026 / 52−26.9%
Reduced / sold out44 / 2036 / 14+28.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NKTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTX is in one of them and how their past NKTX trades turned out.

NKTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NKTX in an article yet. Here's the latest on the wider market.

About Nkarta

Nkarta is a clinical stage biopharmaceutical company based in South San Francisco, California. It develops engineered natural killer cell therapies made from cells donated by healthy people and produced in advance, so they can be given to patients without waiting for a custom batch. Its lead product candidate, NKX019, targets CD19 and is being studied in autoimmune diseases such as lupus nephritis and systemic sclerosis. The company aims its therapies at people living with these conditions.

Headquarters
South San Francisco, CA